1)Shenkier TN, Connoers JM:Primary extranodal non-Hodgkins lymphoma of the ocular adnexa. Acta Oncologica 40:485-490, 2000
2)Guidoboni M, Ferreri AJ, Ponzoni M et al:Infectious agents in mucosa-associated lymphoid tissue-type lymphomas:pathogenic role and therapeutic perspectives. Clin Lymphoma Myeloma 6:289-300, 2006
3)葉山優香・井出尚史・嘉山尚幸・他:眼窩内に再発したマントル細胞リンパ腫の1例.臨眼63:967-972,2009
4)Fisher RI, Dahlberg S, Nathwani BN et al:A clinical analysis of two indolent lymphoma entities:mantle cell lymphoma and marginal zone lymphoma(including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories):a South-west Oncology Group study. Blood 85:1075-1082, 1995
5)Teodorovic I, Pittaluga S, Kluin-Nelemans JC et al:Efficacy of four different regimens in 64 mantle-cell lymphoma cases:clinicopathologic comparison with 498 other non-Hodgkins lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 13:2819-2826, 1995
6)The Non-Hodgkins Lymphoma Classification Project:A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgikins lymphoma. Blood 89:3909-3918, 1997
7)Yatabe Y, Suzuki R, Tobinai K et al:Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma:a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood 95:2253-2261, 2000
8)半田幸助・岡本昌隆:マントル細胞リンパ腫の標準治療.血液フロンティア18:123-132,2008
9)Sasai K, Yamabe H, Dodo Y et al:Non-Hodgkins lymphoma of the ocular adnexa. Acta Oncol 40:485-490, 2001
10)Howard OM, Gribben JG, Neuberg DS et al:Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma:molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002
11)日本血液学会:造血器腫瘍診療ガイドライン.2013